Economic burden of interstitial lung disease in a commercially insured population with Sjogren syndrome in the United States.

ABSTRACT: BACKGROUND: Patients with Sjögren syndrome (SjS) have substantial cost burden on the health care system; among these patients, those who develop interstitial lung disease (ILD) experience poorer quality of life and have a higher mortality risk. However, the economic burden of ILD has not been documented. OBJECTIVE: To estimate the direct health care costs associated with ILD among patients with SjS in a representative sample of the commercially insured population in the United States. METHODS: Individuals with a diagnosis of SjS between January 1, 2006, and September 30, 2015, with and without a diagnosis of ILD, were identified from the PharMetrics Plus for Academics database. The index date was defined as the later date of the first claim with a diagnosis of SjS or t

SUBMITTER: Lee TY 

PROVIDER: S-EPMC10372984 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature